MD4538B1 - 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei - Google Patents
1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofrenieiInfo
- Publication number
- MD4538B1 MD4538B1 MDA20140004A MD20140004A MD4538B1 MD 4538 B1 MD4538 B1 MD 4538B1 MD A20140004 A MDA20140004 A MD A20140004A MD 20140004 A MD20140004 A MD 20140004A MD 4538 B1 MD4538 B1 MD 4538B1
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- indanes
- piperazino
- deuterated
- phenyl
- Prior art date
Links
- QPABODDHXQJCDN-UHFFFAOYSA-N 1-(3-phenyl-2,3-dihydro-1h-inden-1-yl)piperazine Chemical class C12=CC=CC=C2C(C=2C=CC=CC=2)CC1N1CCNCC1 QPABODDHXQJCDN-UHFFFAOYSA-N 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 abstract 1
- 108091005479 5-HT2 receptors Proteins 0.000 abstract 1
- 102000015554 Dopamine receptor Human genes 0.000 abstract 1
- 108050004812 Dopamine receptor Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Invenţia se referă la 1-piperazino-3-fenil-indani deuteraţi, la sărurile acestora cu activitate la nivelul receptorilor D1 şi D2 ai dopaminei, precum şi al receptorilor 5HT2 ai serotoninei din sistemul nervos central, la medicamente care conţin asemenea compuşi în calitate de ingrediente active, la utilizarea unor astfel de compuşi în tratamentul afecţiunilor sistemului nervos central şi la metode de tratament, care prevăd administrarea unor asemenea compuşi.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498651P | 2011-06-20 | 2011-06-20 | |
US201161537103P | 2011-09-21 | 2011-09-21 | |
PCT/IB2012/001386 WO2012176066A1 (en) | 2011-06-20 | 2012-06-19 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |
Publications (3)
Publication Number | Publication Date |
---|---|
MD20140004A2 MD20140004A2 (ro) | 2014-05-31 |
MD4538B1 true MD4538B1 (ro) | 2017-12-31 |
MD4538C1 MD4538C1 (ro) | 2018-07-31 |
Family
ID=46682855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20140004A MD4538C1 (ro) | 2011-06-20 | 2012-06-19 | 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei |
Country Status (40)
Country | Link |
---|---|
US (8) | US8575174B2 (ro) |
EP (4) | EP2720989B1 (ro) |
JP (1) | JP5668177B2 (ro) |
KR (2) | KR101939546B1 (ro) |
CN (1) | CN103649019B (ro) |
AP (1) | AP3310A (ro) |
AR (1) | AR086987A1 (ro) |
AU (1) | AU2012273657B2 (ro) |
BR (1) | BR112013031702B1 (ro) |
CA (1) | CA2837820C (ro) |
CL (1) | CL2013003646A1 (ro) |
CO (1) | CO6821965A2 (ro) |
CR (1) | CR20130654A (ro) |
CY (2) | CY1118158T1 (ro) |
DK (2) | DK2720989T3 (ro) |
DO (1) | DOP2013000305A (ro) |
EA (1) | EA024651B1 (ro) |
EC (1) | ECSP14013155A (ro) |
ES (3) | ES2601213T3 (ro) |
GE (1) | GEP201706655B (ro) |
GT (1) | GT201300304A (ro) |
HK (1) | HK1197228A1 (ro) |
HR (2) | HRP20161348T1 (ro) |
HU (2) | HUE030883T2 (ro) |
IL (1) | IL229640B (ro) |
JO (1) | JO3128B1 (ro) |
LT (2) | LT3135656T (ro) |
MA (1) | MA35268B1 (ro) |
MD (1) | MD4538C1 (ro) |
ME (2) | ME03375B (ro) |
MX (1) | MX339552B (ro) |
MY (1) | MY196998A (ro) |
PE (2) | PE20141113A1 (ro) |
PL (2) | PL2720989T3 (ro) |
PT (2) | PT3135656T (ro) |
RS (2) | RS55304B1 (ro) |
SI (2) | SI3135656T1 (ro) |
SM (1) | SMT201600383B (ro) |
TW (3) | TWI659741B (ro) |
WO (1) | WO2012176066A1 (ro) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5668177B2 (ja) | 2011-06-20 | 2015-02-12 | ハー・ルンドベック・アクチエゼルスカベット | 統合失調症の治療のための重水素化1−ピペラジノ−3−フェニルインダン |
AR094054A1 (es) * | 2012-12-19 | 2015-07-08 | H Lundbeck As | 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma |
WO2019049918A1 (en) | 2017-09-07 | 2019-03-14 | Otsuka Pharmaceutical Co., Ltd. | INDUSTRIAL PROCESS FOR MONOALKYLATION OF PIPERIDINE NITROGEN IN PIPERIDINE DERIVATIVES WITH DEUTERATED ALKYL |
CN112930341A (zh) | 2018-10-29 | 2021-06-08 | H.隆德贝克有限公司 | 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐 |
WO2020114853A1 (en) | 2018-12-03 | 2020-06-11 | H. Lundbeck A/S | Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine |
KR20210124976A (ko) * | 2018-12-21 | 2021-10-15 | 콘서트 파마슈티컬즈, 인크. | 볼리난세린의 중수소화 형태 및 유도체 |
EP3939954A4 (en) | 2019-03-13 | 2023-01-04 | Otsuka Pharmaceutical Co., Ltd. | METHOD FOR INTRODUCING A DEUTERED LOWER ALKYL INTO AN AMINE FRACTION OF A COMPOUND CONTAINING A SECONDARY AMINE |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0035363A1 (en) * | 1980-02-29 | 1981-09-09 | Kefalas A/S | Indane derivatives, methods of their preparation and compositions containing them |
EP0638073B1 (en) * | 1992-04-28 | 2000-06-21 | H. Lundbeck A/S | 1-piperazino-1,2-dihydroindene derivatives |
WO2005016901A1 (en) * | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
US20080269248A1 (en) * | 2005-02-16 | 2008-10-30 | H. Lundbeck A/S | Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine |
US7648991B2 (en) * | 2005-02-16 | 2010-01-19 | H. Lundbeck A/S | Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
US20100069676A1 (en) * | 2005-02-16 | 2010-03-18 | H. Lundbeck A/S | Process for making trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
US20110178094A1 (en) * | 2008-10-03 | 2011-07-21 | H. Lundbeck A/S | Oral Formulation |
US20110207744A1 (en) * | 2008-05-07 | 2011-08-25 | H. Lundbeck A/S | Method for treating cognitive deficits |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8427125D0 (en) | 1984-10-26 | 1984-12-05 | Lundbeck & Co As H | Organic compounds |
DK286990D0 (da) | 1990-12-04 | 1990-12-04 | Lundbeck & Co As H | Indanderivater |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
KR100477070B1 (ko) * | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
AR045279A1 (es) * | 2003-08-18 | 2005-10-19 | Lundbeck & Co As H | Trans-1-(6-cloro-3-fenilindan-1-il)-3,3-dimetilpiperazina |
ES2396365T3 (es) | 2005-07-29 | 2013-02-21 | Concert Pharmaceuticals Inc. | Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
EP1954669B1 (en) | 2005-12-01 | 2015-07-08 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
JP4986462B2 (ja) | 2006-01-27 | 2012-07-25 | シャープ株式会社 | 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
WO2008128166A1 (en) | 2007-04-13 | 2008-10-23 | Concert Pharmaceuticals Inc. | Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds |
KR20100105802A (ko) | 2007-04-19 | 2010-09-29 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
JP2010529196A (ja) | 2007-06-12 | 2010-08-26 | コンサート ファーマシューティカルズ インコーポレイテッド | アザペプチド誘導体 |
US20090062303A1 (en) | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched ziprasidone |
WO2010062656A2 (en) | 2008-10-28 | 2010-06-03 | Concert Pharmaceuticals Inc. | Deuterated 2-propylpentanoic acid compounds |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
US8658236B2 (en) * | 2009-08-21 | 2014-02-25 | Deuteria Beverages, Llc | Alcoholic compositions having a lowered risk of acetaldehydemia |
CN102020522A (zh) * | 2009-09-21 | 2011-04-20 | 陈松源 | 氘代药物的制备方法和应用 |
WO2011047315A1 (en) | 2009-10-15 | 2011-04-21 | Concert Pharmaceuticals, Inc. | Subsitituted benzimidazoles |
WO2011059080A1 (ja) * | 2009-11-16 | 2011-05-19 | 第一三共株式会社 | 同位体置換されたジアミン誘導体 |
JP5668177B2 (ja) | 2011-06-20 | 2015-02-12 | ハー・ルンドベック・アクチエゼルスカベット | 統合失調症の治療のための重水素化1−ピペラジノ−3−フェニルインダン |
-
2012
- 2012-06-19 JP JP2014516459A patent/JP5668177B2/ja active Active
- 2012-06-19 HU HUE12748046A patent/HUE030883T2/en unknown
- 2012-06-19 EA EA201490045A patent/EA024651B1/ru not_active IP Right Cessation
- 2012-06-19 EP EP12748046.5A patent/EP2720989B1/en active Active
- 2012-06-19 BR BR112013031702-7A patent/BR112013031702B1/pt active IP Right Grant
- 2012-06-19 AR ARP120102179 patent/AR086987A1/es active IP Right Grant
- 2012-06-19 PL PL12748046T patent/PL2720989T3/pl unknown
- 2012-06-19 DK DK12748046.5T patent/DK2720989T3/en active
- 2012-06-19 RS RS20160916A patent/RS55304B1/sr unknown
- 2012-06-19 RS RS20190429A patent/RS58546B1/sr unknown
- 2012-06-19 KR KR1020187018343A patent/KR101939546B1/ko active IP Right Grant
- 2012-06-19 MD MDA20140004A patent/MD4538C1/ro active IP Right Grant
- 2012-06-19 MX MX2013014849A patent/MX339552B/es active IP Right Grant
- 2012-06-19 EP EP16179882.2A patent/EP3135656B1/en active Active
- 2012-06-19 GE GEAP201213350A patent/GEP201706655B/en unknown
- 2012-06-19 PT PT16179882T patent/PT3135656T/pt unknown
- 2012-06-19 PE PE2013002857A patent/PE20141113A1/es not_active Application Discontinuation
- 2012-06-19 CN CN201280029731.8A patent/CN103649019B/zh active Active
- 2012-06-19 MY MYPI2021002383A patent/MY196998A/en unknown
- 2012-06-19 LT LTEP16179882.2T patent/LT3135656T/lt unknown
- 2012-06-19 EP EP19151618.6A patent/EP3508468B1/en active Active
- 2012-06-19 LT LTEP12748046.5T patent/LT2720989T/lt unknown
- 2012-06-19 EP EP23150855.7A patent/EP4215512A1/en active Pending
- 2012-06-19 US US13/527,364 patent/US8575174B2/en active Active
- 2012-06-19 DK DK16179882.2T patent/DK3135656T3/en active
- 2012-06-19 ES ES12748046.5T patent/ES2601213T3/es active Active
- 2012-06-19 PT PT127480465T patent/PT2720989T/pt unknown
- 2012-06-19 PE PE2015000596A patent/PE20150928A1/es active IP Right Grant
- 2012-06-19 ES ES19151618T patent/ES2939477T3/es active Active
- 2012-06-19 ME MEP-2019-93A patent/ME03375B/me unknown
- 2012-06-19 JO JOP/2012/0161A patent/JO3128B1/ar active
- 2012-06-19 ME MEP-2016-226A patent/ME02513B/me unknown
- 2012-06-19 KR KR1020137033717A patent/KR101879474B1/ko active IP Right Grant
- 2012-06-19 HU HUE16179882A patent/HUE044043T2/hu unknown
- 2012-06-19 SI SI201231582T patent/SI3135656T1/sl unknown
- 2012-06-19 ES ES16179882T patent/ES2719145T3/es active Active
- 2012-06-19 AP AP2013007338A patent/AP3310A/xx active
- 2012-06-19 SI SI201230744A patent/SI2720989T1/sl unknown
- 2012-06-19 PL PL16179882T patent/PL3135656T3/pl unknown
- 2012-06-19 AU AU2012273657A patent/AU2012273657B2/en active Active
- 2012-06-19 CA CA2837820A patent/CA2837820C/en active Active
- 2012-06-19 WO PCT/IB2012/001386 patent/WO2012176066A1/en active Application Filing
- 2012-06-20 TW TW107113541A patent/TWI659741B/zh active
- 2012-06-20 TW TW101122028A patent/TWI627956B/zh active
- 2012-06-20 TW TW106107563A patent/TWI614234B/zh active
-
2013
- 2013-06-24 US US13/924,849 patent/US9012453B2/en active Active
- 2013-11-26 IL IL229640A patent/IL229640B/en active IP Right Grant
- 2013-12-09 GT GT201300304A patent/GT201300304A/es unknown
- 2013-12-13 CR CR20130654A patent/CR20130654A/es unknown
- 2013-12-16 DO DO2013000305A patent/DOP2013000305A/es unknown
- 2013-12-19 CL CL2013003646A patent/CL2013003646A1/es unknown
- 2013-12-19 CO CO13296680A patent/CO6821965A2/es active IP Right Grant
-
2014
- 2014-01-16 MA MA36688A patent/MA35268B1/fr unknown
- 2014-01-17 EC ECSP14013155 patent/ECSP14013155A/es unknown
- 2014-10-22 HK HK14110519A patent/HK1197228A1/zh unknown
-
2015
- 2015-03-13 US US14/656,925 patent/US9216961B2/en active Active
- 2015-11-16 US US14/941,800 patent/US9617231B2/en active Active
-
2016
- 2016-10-17 HR HRP20161348TT patent/HRP20161348T1/hr unknown
- 2016-10-26 CY CY20161101089T patent/CY1118158T1/el unknown
- 2016-10-26 SM SM201600383T patent/SMT201600383B/it unknown
-
2017
- 2017-02-17 US US15/435,826 patent/US10118907B2/en active Active
-
2018
- 2018-09-28 US US16/146,625 patent/US10501427B2/en active Active
-
2019
- 2019-03-27 HR HRP20190593TT patent/HRP20190593T1/hr unknown
- 2019-04-02 CY CY20191100368T patent/CY1121514T1/el unknown
- 2019-11-04 US US16/672,870 patent/US11059798B2/en active Active
-
2021
- 2021-06-07 US US17/340,201 patent/US20220119362A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0035363A1 (en) * | 1980-02-29 | 1981-09-09 | Kefalas A/S | Indane derivatives, methods of their preparation and compositions containing them |
EP0638073B1 (en) * | 1992-04-28 | 2000-06-21 | H. Lundbeck A/S | 1-piperazino-1,2-dihydroindene derivatives |
WO2005016901A1 (en) * | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
US20080269248A1 (en) * | 2005-02-16 | 2008-10-30 | H. Lundbeck A/S | Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine |
US7648991B2 (en) * | 2005-02-16 | 2010-01-19 | H. Lundbeck A/S | Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
US20100069676A1 (en) * | 2005-02-16 | 2010-03-18 | H. Lundbeck A/S | Process for making trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
US20110207744A1 (en) * | 2008-05-07 | 2011-08-25 | H. Lundbeck A/S | Method for treating cognitive deficits |
US20110178094A1 (en) * | 2008-10-03 | 2011-07-21 | H. Lundbeck A/S | Oral Formulation |
Non-Patent Citations (5)
Title |
---|
Hiroshi Kashihara, Hiroshi Shinoki, Hiroshi Suemune, Kiyoshi Sakai. Novel Synthesis of Indan Derivatives. Chemical and Pharmaceutical Bulletin, 1986, vol. 34, nr. 11, p. 4527-4532 * |
Joseph P. Simeone, John R. Sowa Jr. Palladium on carbon as a precatalyst for the Suzuki-Miyuara cross-coupling of aryl chlorides. Tetrahedron, 2007, vol. 63, nr. 51, p. 12646-12654 * |
Jun Takagi, Kou Takahashi, Tatsuo Ishiyama, Norio Miyaura. Palladium-Catalyzed Cross-Coupling Reaction of Bis(pinacolato)diboron with 1-Alkenyl Halides or Triflates: Convenient Synthesis of Unsymmetrical 1,3-Dienes via the Borylation-Coupling Sequence. Journal of The American Chemical Society, 2002, vol. 124, p. 8001-8006 * |
Klaus P. Bogeso et al. Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindans with Potential Atypical Antipsychotic Activity. Journal of Medicinal Chemistry, 1995, vol. 38, p. 4380-4392 * |
Kousik Kundu, James V. McCullagh, Andrew T. Morehead Jr. Hydroacylation of 2-Vinyl Benzaldehyde Systems: An Efficient Method for the Synthesis of Chiral 3-Substituted Indanones. Journal of the American Chemical Society, 2005, vol. 127, nr. 46, p. 16042-16043 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX349754B (es) | Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia. | |
IN2014DN09434A (ro) | ||
MD4538C1 (ro) | 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei | |
MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
EA201400569A1 (ru) | Новые производные циклогексиламина, обладающие агонистической активностью по отношению к бета-2 адренергическому рецептору и антагонистической активностью по отношению к мускариновому рецептору м3 | |
EA201400567A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 | |
CL2014002935A1 (es) | Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador | |
UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
UA109260C2 (uk) | Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування | |
EA201500651A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 | |
MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
GB201115977D0 (en) | Neurodevelopmental disorders | |
TN2013000503A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
MY166773A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
EP3064201A4 (en) | Pharmaceutical composition for preventing and treating central nervous system diseases containing fluoxetine and vitamin c as active ingredients | |
EA201500366A1 (ru) | Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора | |
UA65038U (ru) | Способ лечения больных послеродовыми психозами |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG4A | Patent for invention issued |